Journal
ANNALS OF ONCOLOGY
Volume 27, Issue 7, Pages 1354-1356Publisher
OXFORD UNIV PRESS
DOI: 10.1093/annonc/mdw148
Keywords
-
Categories
Ask authors/readers for more resources
Unexpected severe exacerbation or manifestation of primary disease related to nivolumab was noted in non-small-cell lung cancer (NSCLC) patients with a poor performance status or central nervous system metastases. Thus, we should monitor these patients when they are administered nivolumab.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available